twoplus fertility vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Singapore at-home fertility applicator for natural conception avoiding costly IVF/IUI; YC S20 $5.3M Monk's Hill Ventures-backed revenue-generating 2024 in SG/UK/US competing with Mosie Baby and Natalist for consumer fertility health products.
About
Twoplus Fertility is a Singapore-based consumer fertility health company — backed by Y Combinator (S20) with $5.3 million raised including a $5.15 million seed round led by Monk's Hill Ventures in May 2022 — providing couples experiencing difficulty conceiving with at-home fertility products designed as non-invasive, affordable alternatives to clinical fertility treatments, starting with the Twoplus Sperm Guide applicator (an at-home cervical cap applicator that positions sperm closer to the cervix during natural conception attempts, increasing the probability of fertilization for couples with mild male factor infertility or unexplained subfertility). Founded in 2019 by Prusothman Raja and Benjamin Tee, Twoplus became revenue-generating in 2024 and distributes products in Singapore, the United Kingdom, and the United States.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.